# To Explore the Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer 's Disease

> **NCT06393413** · EARLY_PHASE1 · COMPLETED · sponsor: **Changchun University of Chinese Medicine** · enrollment: 62 (actual)

## Conditions studied

- Ensure the Legality and Compliance of the Testing Process

## Interventions

- **DRUG:** Jiedu Yizhi Formula
- **DRUG:** Donepezil Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT06393413
- **Lead sponsor:** Changchun University of Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393413, "To Explore the Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer 's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06393413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*